BlackRock, Inc. 13D and 13G filings for Neurocrine Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-01-23 11:52 am Purchase | 2023-12-31 | 13G | Neurocrine Biosciences, Inc. NBIX | BlackRock Inc. BLK | 13,647,679 13.900% | 1,020,276 (+8.08%) | Filing |
| 2023-01-23 3:52 pm Purchase | 2022-12-31 | 13G | Neurocrine Biosciences, Inc. NBIX | BlackRock Inc. BLK | 12,627,403 13.100% | 1,150,858 (+10.03%) | Filing |
| 2022-01-27 1:59 pm Unchanged | 2021-12-31 | 13G | Neurocrine Biosciences, Inc. NBIX | BlackRock Inc. BLK | 11,476,545 12.100% | 0 (Unchanged) | Filing |
| 2022-01-25 6:45 pm Purchase | 2021-12-31 | 13G | Neurocrine Biosciences, Inc. NBIX | BlackRock Inc. BLK | 11,476,545 12.100% | 486,899 (+4.43%) | Filing |
| 2021-04-09 6:00 pm Purchase | 2021-03-31 | 13G | Neurocrine Biosciences, Inc. NBIX | BlackRock Inc. BLK | 10,989,646 11.700% | 3,991,851 (+57.04%) | Filing |
| 2021-01-29 5:23 pm Purchase | 2020-12-31 | 13G | Neurocrine Biosciences, Inc. NBIX | BlackRock Inc. BLK | 6,997,795 7.500% | 406,243 (+6.16%) | Filing |